Royalty Pharma PLC (RPRX) to Distribute Quarterly Dividend of $0.23 on December 10th

Posted by Brian Himes on Oct 18th, 2026

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) announced a quarterly dividend on Friday, October 16th. Investors of record on Friday, November 13th will be given a dividend of $0.2350 per share by the biopharmaceutical company on Thursday, December 10th. This represents a $0.94 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend is Friday, November 13th.

Royalty Pharma has increased its dividend payment by an average of 0.2% per year over the last three years and has increased its dividend every year for the last 5 years. Royalty Pharma has a payout ratio of 18.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $5.63 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 16.7%.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $60.96 on Friday. Royalty Pharma has a 12-month low of $35.92 and a 12-month high of $64.38. The company has a market capitalization of $35.05 billion, a price-to-earnings ratio of 42.04, a price-to-earnings-growth ratio of 1.67 and a beta of 0.42. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The firm’s fifty day moving average price is $59.42 and its 200 day moving average price is $55.71.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. On average, research analysts forecast that Royalty Pharma will post 5.29 EPS for the current fiscal year.

Insider Transactions at Royalty Pharma

In other news, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at $15,826,570.53. This trade represents a 27.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,252 shares of company stock valued at $12,324,407 over the last quarter. Insiders own 18.84% of the company’s stock.

Institutional Trading of Royalty Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. grew its position in shares of Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 437 shares during the last quarter. CoreCap Advisors LLC raised its stake in Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 413 shares in the last quarter. Bessemer Group Inc. boosted its position in Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 282 shares during the period. IFP Advisors Inc boosted its position in Royalty Pharma by 263.3% during the 2nd quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 861 shares during the period. Finally, Oslo Pensjonsforsikring AS acquired a new position in Royalty Pharma during the 1st quarter worth $95,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.